Drug Profile
BIO 203
Alternative Names: BIO2003Latest Information Update: 01 Oct 2015
Price :
$50
*
At a glance
- Originator Gardant Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Candidiasis; Oropharyngeal candidiasis
Most Recent Events
- 04 Jan 2007 Gardant Pharmaceuticals has been acquired by Switch Pharma
- 21 Oct 2005 Phase-I clinical trials in Candidiasis in USA (unspecified route)
- 21 Oct 2005 Phase-I clinical trials in Oropharyngeal candidiasis in USA (unspecified route)